GI Cancer Conference Review 2007- reviewed by Dr Dragan Damianovich

In this issue:

Cetuximab + FOLFOX-4 active in mCRC
Cetuximab + capecitabine:  increased toxicity
Bevacizumab + irinotecan + 5-FU/LV in mCRC
Bevacizumab + common CT regimens in mCRC
XELOX vs FOLFOX4: first-line in mCRC
Prolonging bevacizumab improves outcomes
Peri-operative chemotherapy advantageous
Incorporating panitumumab in mCRC regimens
Benefits with cetuximab dose-escalation
FDG-PET may reduce futile laparotomies

Download PDF Subscribe